Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)

NCT01669707 is registered in ClinicalTrials.gov with Beijing Chest Hospital as lead sponsor.

NCT NCT01669707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01669707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Beijing Chest Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2011
Completion date
September 30, 2020
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer